PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 1993 June; 67(6): 1385–1390.
PMCID: PMC1968524

A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.

Abstract

One hundred and fifty-nine previously untreated patients with small cell lung cancer (SCLC), who were not eligible for intensive chemotherapy, were entered into a randomised study of intravenous (i.v.) doxorubicin and ifosfamide (with mesna) and oral etoposide. The i.v. drugs were given either by bolus therapy or by a continuous infusion (CI) pump over 7 days via a central venous line. Therapy was given for 6 weeks only. On weeks 1, 3 and 5 IV doxorubicin 35 mg m-2 was given with 5 days of oral etoposide 100 mg m-2 daily. On weeks 2, 4 and 6 IV ifosfamide 5 g m-2 was given with equidose mesna. The overall median survival was 25 weeks for patients in the bolus arm and 30 weeks for the CI therapy (P = 0.45). The overall response rate was 64% (18% complete response-CR) and 69% (30% CR) respectively (P = 0.13). The median WHO score for haematological toxicity was 4 for bolus therapy and 3 for CI therapy (P = 0.0007). Despite a trend for less supportive care for patients on CI therapy there were no significant differences in the use of i.v. antibodies and blood or platelet transfusions. There were fewer treatment delays due to myelotoxicity in the CI arm (P = 0.04). The median WHO score for non-haematological toxicity was 2 in both treatment groups. There was significantly less nausea (P = 0.037) but more mucositis (P = 0.01) in the CI arm. Weekly chemotherapy using CI treatment was as effective as bolus therapy. It was well accepted by patients. The assessment of quality of life in a subgroup of patients showed a statistically significant reduction in anxiety and depression for both groups of patients during therapy.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Anderson H, Lind MJ, Thatcher N, Swindell R, Woodcock A, Carroll KB. Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide. Cancer Chemother Pharmacol. 1990;26(1):71–74. [PubMed]
  • Blackledge G, Bush H, Chang J, Crowther D, Deakin DP, Dodge OG, Garrett JV, Palmer M, Pearson D, Scarffe JH, et al. Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma. (A report of 89 cases with extensive disease from the Manchester Lymphoma Group). Eur J Cancer. 1980 Nov;16(11):1459–1468. [PubMed]
  • Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer. 1989 Apr;59(4):584–590. [PMC free article] [PubMed]
  • Bosanquet AG. Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents. Cancer Chemother Pharmacol. 1985;14(2):83–95. [PubMed]
  • Brade WP, Herdrich K, Varini M. Ifosfamide--pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985 Mar;12(1):1–47. [PubMed]
  • Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987 Feb 15;39(2):146–149. [PubMed]
  • Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MH, Byrne M, Harvey V, Gill G. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987 Dec 10;317(24):1490–1495. [PubMed]
  • de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990 Dec;62(6):1034–1038. [PMC free article] [PubMed]
  • Earl HM, Rudd RM, Spiro SG, Ash CM, James LE, Law CS, Tobias JS, Harper PG, Geddes DM, Eraut D, et al. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1991 Sep;64(3):566–572. [PMC free article] [PubMed]
  • Hopwood P, Thatcher N. Preliminary experience with quality of life evaluation in patients with lung cancer. Oncology (Williston Park) 1990 May;4(5):158–171. [PubMed]
  • Hopwood P, Thatcher N. Current status of quality of life measurement in lung cancer patients. Oncology (Williston Park) 1991 May;5(5):159–173. [PubMed]
  • Issell BF. The podophyllotoxin derivatives VP16-213 and VM26. Cancer Chemother Pharmacol. 1982;7(2-3):73–80. [PubMed]
  • Kamthan AG, Lind MJ, Thatcher N, Steward WP, Bronchud MH, Ranson MR, Stout R. Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis. Eur J Cancer. 1990;26(6):691–694. [PubMed]
  • Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985 May;102(5):596–602. [PubMed]
  • Maguire P, Selby P. Assessing quality of life in cancer patients. Br J Cancer. 1989 Sep;60(3):437–440. [PMC free article] [PubMed]
  • Miles DW, Earl HM, Souhami RL, Harper PG, Rudd R, Ash CM, James L, Trask CW, Tobias JS, Spiro SG. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol. 1991 Feb;9(2):280–285. [PubMed]
  • Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. [PubMed]
  • Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E, Minna JD. Small cell lung cancer 1973-1983: early progress and recent obstacles. Int J Radiat Oncol Biol Phys. 1984 Apr;10(4):515–539. [PubMed]
  • Murray N, Shah A, Osoba D, Page R, Karsai H, Grafton C, Goddard K, Fairey R, Voss N. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol. 1991 Sep;9(9):1632–1638. [PubMed]
  • Radford JA, Margison JM, Swindell R, Lind MJ, Wilkinson PM, Thatcher N. The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. Cancer Chemother Pharmacol. 1990;26(2):144–146. [PubMed]
  • Richards MA, Hopwood P, Ramirez AJ, Twelves CJ, Ferguson J, Gregory WM, Swindell R, Scrivener W, Miller J, Howell A, et al. Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer. 1992;28A(6-7):1023–1028. [PubMed]
  • Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, Tobias JS, Partridge M, Eraut D. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989 Apr;59(4):578–583. [PMC free article] [PubMed]
  • Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D, Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377–1387. [PubMed]
  • Taylor CW, Crowley J, Williamson SK, Miller TP, Taylor SA, Giri TG, Stephens RL, Livingston RB. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. J Clin Oncol. 1990 Nov;8(11):1811–1817. [PubMed]
  • Thatcher N, Barber PV, Hunter RD, Carroll KB, Jegarajah S, Wilkinson PM, Crowther D. 11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group. Lancet. 1982 May 8;1(8280):1040–1043. [PubMed]
  • Thatcher N, James RD, Steward WP, Barber PV, Feinmann D, Lawson BA, Carroll KB. Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer. Cancer. 1985 Sep 15;56(6):1332–1336. [PubMed]
  • Vogelzang NJ. Continuous infusion chemotherapy: a critical review. J Clin Oncol. 1984 Nov;2(11):1289–1304. [PubMed]
  • Workman P. Infusional anthracyclines: is slower better? If so, why? Ann Oncol. 1992 Sep;3(8):591–594. [PubMed]
  • Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–370. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK